Formerly known as A.P. Pharma, Inc. (NASDAQ:APPA) and Advanced PolymerSystems, the firm's name was changed in August, 2013 to Heron Therapeutics, Inc.. Heron Therapeutics is a specialty pharmaceutical company developing products using its proprietary Biochronomer⢠polymer-based drug delivery platform. This drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by converting them from products that must be injected once or twice per day to products that need to be injected only once every one or two weeks. The Companyâs lead product candidate, APF530, is being developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting. The Company has also developed a second family of polymers (collectively, block copolymers of poly(ortho esters) and poly(ethylene glycol)) under the trade name Bioerodimer. Initial targeted areas of application for the Company's drug delivery technologies include pain management; anti-inflammatory, oncology and ophthalmology applications; device coatings, and DNA delivery. In February 2003, the Company sold the assets of APS Analytical Standards, Inc., a wholly owed subsidiary through which the company engaged in developing microspheres for use as a testing standard for gauging the purity of municipal drinking wat
